Copyright: ©Author(s) 2026.
World J Gastrointest Surg. Nov 27, 2026; 18(11): 122614
Published online Nov 27, 2026. doi: 10.4240/wjgs.122614
Published online Nov 27, 2026. doi: 10.4240/wjgs.122614
Table 5 Univariate analysis, n (%)
| Data | Ineffective group (n = 35) | Effective group (n = 163) | χ2 | P value |
| Sex | 0.117 | 0.733 | ||
| Male (n = 107) | 18 (51.43) | 89 (54.60) | ||
| Female (n = 91) | 17 (48.57) | 74 (45.40) | ||
| Age (years) | 4.888 | 0.027 | ||
| < 56 (n = 90) | 10 (28.57) | 80 (49.08) | ||
| ≥ 56 (n = 108) | 25 (71.43) | 83 (50.92) | ||
| Body mass index (kg/m2) | 0.075 | 0.784 | ||
| < 23 (n = 89) | 15 (42.86) | 74 (45.40) | ||
| ≥ 23 (n = 109) | 20 (57.14) | 89 (54.60) | ||
| Anesthesia mode | 0.027 | 0.870 | ||
| General anesthesia (n = 93) | 16 (45.71) | 77 (47.24) | ||
| Epidural anesthesia (n = 105) | 19 (54.29) | 86 (52.76) | ||
| Surgical modality | 1.720 | 0.423 | ||
| Gastroduodenostomy (n = 78) | 16 (45.71) | 62 (38.04) | ||
| Gastrojejunostomy (n = 51) | 6 (17.14) | 45 (27.61) | ||
| Roux-en-Y anastomosis (n = 69) | 13 (37.14) | 56 (34.36) | ||
| TNM staging | 7.586 | 0.006 | ||
| I-IIA (n = 68) | 5 (14.29) | 63 (38.65) | ||
| IIB-III (n = 130) | 30 (85.71) | 100 (61.35) | ||
| Surgical duration (hours) | 4.888 | 0.027 | ||
| < 4 (n = 90) | 10 (28.57) | 80 (49.08) | ||
| ≥ 4 (n = 108) | 25 (71.43) | 83 (50.92) | ||
| Baseline nausea and vomiting (points) | 0.090 | 0.764 | ||
| < 2 (n = 55) | 9 (25.71) | 46 (28.22) | ||
| ≥ 2 (n = 143) | 26 (74.29) | 117 (71.78) | ||
| Baseline stomach distension (points) | 1.282 | 0.258 | ||
| < 2 (n = 55) | 7 (20.00) | 48 (29.45) | ||
| ≥ 2 (n = 143) | 28 (80.00) | 115 (70.55) | ||
| Baseline inability to eat a normal amount of food (points) | 0.011 | 0.916 | ||
| < 3 (n = 72) | 13 (37.14) | 59 (36.20) | ||
| ≥ 3 (n = 126) | 22 (62.86) | 104 (63.80) | ||
| Baseline inappetence (points) | 1.601 | 0.206 | ||
| < 2 (n = 46) | 11 (31.43) | 35 (21.47) | ||
| ≥ 2 (n = 152) | 24 (68.57) | 128 (78.53) | ||
| Baseline severe postprandial fullness (points) | 0.024 | 0.877 | ||
| < 2 (n = 53) | 9 (25.71) | 44 (26.99) | ||
| ≥ 2 (n = 145) | 26 (74.29) | 119 (73.01) | ||
| Baseline gastrin (ng/L) | 5.357 | 0.021 | ||
| < 88 (n = 95) | 23 (65.71) | 72 (44.17) | ||
| ≥ 88 (n = 103) | 12 (34.29) | 91 (55.83) | ||
| Baseline motilin (mg/L) | 10.886 | 0.001 | ||
| < 309 (n = 97) | 26 (74.29) | 71 (43.56) | ||
| ≥ 309 (n = 101) | 9 (25.71) | 92 (56.44) | ||
| Therapeutic regimen | 8.353 | 0.004 | ||
| Omeprazole (n = 92) | 24 (68.57) | 68 (41.72) | ||
| Omeprazole + cisapride (n = 106) | 11 (31.43) | 95 (58.28) |
- Citation: Zhu SL, Gao Q, Liu Y, Cheng KP. Omeprazole-cisapride combination for gastroparesis following radical gastrectomy for gastric cancer: An efficacy and safety analysis. World J Gastrointest Surg 2026; 18(11): 122614
- URL: https://www.wjgnet.com/1948-9366/full/v18/i11/122614.htm
- DOI: https://dx.doi.org/10.4240/wjgs.122614